Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neisseria meningitidis serogroup A, C, W-135, and Y capsular polysaccharide antigens are complex carbohydrates located on the outermost surface of the meningococcus bacterium (PubMed, 2023). These polysaccharides serve as critical virulence factors by protecting the pathogen from host immune responses, particularly phagocytosis and complement-mediated killing (StatPearls, 2023). In the context of vaccinology, these specific serogroups are targeted because they are responsible for the majority of invasive meningococcal disease cases globally, including life-threatening meningitis and sepsis (CDC, 2023). Modern vaccines utilize these antigens either as purified polysaccharides or, more commonly, conjugated to carrier proteins to enhance immunogenicity and induce long-term immunological memory (FDA, 2023). Upon administration, the immune system recognizes these antigens and produces bactericidal antibodies that provide protection against future infections by the corresponding serogroups (PubMed, 2023). The interaction between the vaccine and these targets results in the formation of a protective immune barrier that prevents bacterial colonization and systemic spread. This approach has significantly reduced the incidence of meningococcal disease in populations with high vaccination coverage (WHO, 2023).
Induction of active immunity by stimulating the production of serogroup-specific capsular antibodies, which mediate complement-dependent bactericidal activity and opsonophagocytosis of Neisseria meningitidis (FDA, 2023; StatPearls, 2023).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neisseria meningitidis serogroup A, C, W-135, and Y capsular polysaccharide antigen (MenACWY) (MenACWY).